blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...
blank News flashes

Italy joins the Federated Register

Click here for more information on the Federated Register.

2025-06-12

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register User Manual
European Patent Register – pocket guide
FAQ - European Patent Register
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP4159230

EP4159230 - ANTI-ADRENOMEDULLIN (ADM) BINDER FOR USE IN THERAPY OR PREVENTION OF SYMPTOMS OF ILLNESS [Right-click to bookmark this link]
StatusExamination is in progress
Status updated on  22.12.2023
Database last updated on 09.04.2026
FormerRequest for examination was made
Status updated on  06.10.2023
FormerThe application has been published
Status updated on  03.03.2023
Most recent event   Tooltip19.02.2026New entry: Despatch of examination report + time limit 
Applicant(s)For all designated states
AdrenoMed AG
Neuendorfstrasse 15a
16761 Hennigsdorf / DE
[2023/14]
Inventor(s)01 / BERGMANN, Andreas
13465 Berlin / DE
 [2023/14]
Representative(s)Kilger, Ute
Boehmert & Boehmert
Anwaltspartnerschaft mbB
Pettenkoferstrasse 22
80336 München / DE
[2023/14]
Application number, filing date22198142.625.09.2018
[2023/14]
Priority number, dateEP2017019299925.09.2017         Original published format: EP 17192999
EP2017020337023.11.2017         Original published format: EP 17203370
[2023/14]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report 
No.:EP4159230
Date:05.04.2023
Language:EN
[2023/14]
Search report(s)(Supplementary) European search report - dispatched on:EP07.03.2023
ClassificationIPC:A61K39/00, A61P31/00, C07K16/26, C07K16/46
[2023/14]
CPC:
C07K16/26 (EP,CN,IL,KR); C07K16/22 (US); A61K9/0019 (US);
A61P13/12 (CN); A61P17/02 (CN); A61P25/00 (CN);
A61P25/06 (EP,KR); A61P29/00 (CN); A61P3/00 (CN);
A61P3/10 (CN); A61P31/00 (EP,CN,IL); A61P37/02 (EP,CN);
A61P9/04 (CN); A61P9/10 (CN); A61P9/12 (CN);
A61K2039/505 (EP,CN,IL,KR); A61K2039/545 (EP); A61K39/00 (EP,IL,US);
C07K2317/21 (EP,IL,KR); C07K2317/24 (EP,CN,IL,KR); C07K2317/34 (EP,IL);
C07K2317/51 (CN); C07K2317/515 (CN); C07K2317/54 (EP,IL,KR);
C07K2317/55 (EP,IL,KR); C07K2317/56 (CN,US); C07K2317/565 (CN,KR,US);
C07K2317/622 (EP,IL,KR); C07K2317/76 (EP,IL,KR,US); C07K2317/92 (EP,CN,IL,US);
C07K2317/94 (EP,CN,IL); C07K2318/20 (US) (-)
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2023/45]
Former [2023/14]AL,  AT,  BE,  BG,  CH,  CY,  CZ,  DE,  DK,  EE,  ES,  FI,  FR,  GB,  GR,  HR,  HU,  IE,  IS,  IT,  LI,  LT,  LU,  LV,  MC,  MK,  MT,  NL,  NO,  PL,  PT,  RO,  RS,  SE,  SI,  SK,  SM,  TR 
TitleGerman:ANTI-ADRENOMEDULLIN (ADM)-BINDEMITTEL ZUR VERWENDUNG IN DER THERAPIE ODER VORBEUGUNG VON KRANKHEITSSYMPTOMEN[2023/14]
English:ANTI-ADRENOMEDULLIN (ADM) BINDER FOR USE IN THERAPY OR PREVENTION OF SYMPTOMS OF ILLNESS[2023/14]
French:LIANT ANTI-ADRÉNOMÉDULLINE (ADM) DESTINÉ À ÊTRE UTILISÉ DANS LA THÉRAPIE OU LA PRÉVENTION DE SYMPTÔMES DE MALADIE[2023/14]
Examination procedure05.10.2023Amendment by applicant (claims and/or description)
05.10.2023Examination requested  [2023/45]
05.10.2023Date on which the examining division has become responsible
02.01.2024Despatch of a communication from the examining division (Time limit: M04)
02.05.2024Reply to a communication from the examining division
18.02.2026Despatch of a communication from the examining division (Time limit: M04)
Parent application(s)   TooltipEP18781997.4  / EP3687567
Fees paidRenewal fee
27.09.2022Renewal fee patent year 03
27.09.2022Renewal fee patent year 04
27.09.2022Renewal fee patent year 05
24.08.2023Renewal fee patent year 06
25.09.2024Renewal fee patent year 07
25.09.2025Renewal fee patent year 08
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Documents cited:Search[PIY] WO2018109228  (ADRENOMED AG et al.)
 [A] EP2594587  (ADRENOMED AG et al.)
 [IY]   ANONYMOUS: "Adrecizumab-LPS Study - Full Text View - ClinicalTrials.gov", 21 March 2017 (2017-03-21), XP055460516, Retrieved from the Internet [retrieved on 20180319]
 [A]   JOACHIM STRUCK ET AL: "Epitope specificity of anti-Adrenomedullin antibodies determines efficacy of mortality reduction in a cecal ligation and puncture mouse model", INTENSIVE CARE MEDICINE EXPERIMENTAL, vol. 1, no. 1, 1 January 2013 (2013-01-01), pages 3, XP055460518, ISSN: 2197-425X, DOI: 10.1186/2197-425X-1-3

DOI:   http://dx.doi.org/10.1186/2197-425X-1-3
 [A]   KA PETERSEN ET AL: "Effect of Adrenomedullin on the Cerebral Circulation: Relevance to Primary Headache Disorders", CEPHALALGIA, vol. 29, no. 1, 1 January 2009 (2009-01-01), GB, pages 23 - 30, XP055460712, ISSN: 0333-1024, DOI: 10.1111/j.1468-2982.2008.01695.x

DOI:   http://dx.doi.org/10.1111/j.1468-2982.2008.01695.x
 [A]   ANDREW F. RUSSO: "CGRP as a neuropeptide in migraine: lessons from mice : CGRP as a neuropeptide in migraine", BRITISH JOURNAL OF CLINICAL PHARMACOLOGY., vol. 80, no. 3, 1 September 2015 (2015-09-01), GB, pages 403 - 414, XP055460751, ISSN: 0306-5251, DOI: 10.1111/bcp.12686

DOI:   http://dx.doi.org/10.1111/bcp.12686
   CHRISTOPHER GEVEN ET AL: "Adrenomedullin and Adrenomedullin-Targeted Therapy As Treatment Strategies Relevant for Sepsis", FRONTIERS IN IMMUNOLOGY, vol. 9, 19 February 2018 (2018-02-19), CH, XP055460539, ISSN: 1664-3224, DOI: 10.3389/fimmu.2018.00292

DOI:   http://dx.doi.org/10.3389/fimmu.2018.00292
 [A]   ROSSELLA MARINO ET AL: "Plasma adrenomedullin is associated with short-term mortality and vasopressor requirement in patients admitted with sepsis", CRITICAL CARE, BIOMED CENTRAL LTD LONDON, GB, vol. 18, no. 1, 17 February 2014 (2014-02-17), pages R34, XP021179720, ISSN: 1364-8535, DOI: 10.1186/CC13731

DOI:   http://dx.doi.org/10.1186/cc13731
Examination  O. L. BLANCHARD ET AL: "Translating dosages from animal models to human clinical trials--revisiting body surface area scaling", THE FASEB JOURNAL, vol. 29, no. 5, 5 February 2015 (2015-02-05), US, pages 1629 - 1634, XP055272886, ISSN: 0892-6638, DOI: 10.1096/fj.14-269043

DOI:   http://dx.doi.org/10.1096/fj.14-269043
   CHRISTOPHER GEVEN ET AL: "Safety, tolerability and pharmacokinetics/pharmacodynamics of the adrenomedullin antibody adrecizumab in a first-in-human study and during experimental human endotoxaemia in healthy subjects", BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, BLACKWELL SCIENTIFIC PUBL, GB, vol. 84, no. 9, 3 July 2018 (2018-07-03), pages 2129 - 2141, XP071603032, ISSN: 0306-5251, DOI: 10.1111/BCP.13655

DOI:   http://dx.doi.org/10.1111/bcp.13655
by applicantUS5807715
 US5585089
 WO9117271
 WO9201047
 WO9220791
 WO9312227
 WO9110741
 WO2013072513
 US2010028995
 EP1266025
 WO2011154420
 WO2011073214
 US2004023334
 EP2231860
 WO2010060748
 EP2314308
 WO2011023685
 WO2005040229
 EP1941867
   KITAMURA K. ET AL., BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, vol. 192, no. 2, 1993, pages 553 - 560
   TOMODA Y. ET AL., PEPTIDES, vol. 22, 2001, pages 1835 - 1840
   HINSON ET AL., ENDOCRINE REVIEWS, vol. 21, no. 2, 2000, pages 138 - 167
   KITAMURA K. ET AL., BIOCHEM. BIOPHYS. RES. COMMUN., vol. 244, no. 2, 1998, pages 551 - 555
   PIO R. ET AL., THE JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 276, no. 15, 2001, pages 12292 - 12300
   HIRATA ET AL., JOURNAL OF CLINICAL ENDOCRINOLOGY AND METABOLISM, vol. 81, no. 4, 1996, pages 1449 - 1453
   EHLENZ K. ET AL., EXP CLIN ENDOCRINOL DIABETES, vol. 105, 1997, pages 156 - 162
   UEDA S. ET AL., AM. J. RESPIR. CRIT. CARE MED., vol. 160, 1999, pages 132 - 136
   PETERSEN ET AL., CEPHALALGIA, vol. 29, 2008, pages 23 - 30
   AKCALI A., MEDICAL SCIENCE AND DISCOVERY, vol. 3, no. 4, 2016, pages 153 - 158
   KIS ET AL., HVPERTENS RES, vol. 26, 2003, pages 61 - S70
   METZ A., AUSTRALIAN FAMILY PHYSICIAN, vol. 36, no. 9, 2017, pages 688 - 692
   WALDMAN ET AL., J YOGA PHYS THER, vol. 4, 2014, pages 1
   OLESON, FUNCTIONAL NEUROLOGY, vol. 20, no. 2, 2005, pages 61 - 68
   DIENER ET AL., NAT REV NEUROL., vol. 8, no. 3, 2012, pages 162 - 71
   KVRIAKIDES ET AL., EUROPEAN JOURNAL OF NEUROLOGY, vol. 20, 2013, pages 997 - 1005
   COHEN ET AL., BMJ, vol. 337, 2008, pages a2718
   GOADSBV ET AL., N. ENGL. J. MED., vol. 346, 2002, pages 257 - 270
   LANZAVECCHIA ET AL., EUR. J. IMMUNOL., vol. 17, 1987, pages 105
   HUSTON ET AL., PNAS, vol. 85, 1988, pages 5879 - 5883
   BIRD ET AL., SCIENCE, vol. 242, 1988, pages 423 - 426
   HOOD ET AL., IMMUNOLOGY. BENJAMIN. N.Y., 1984
   JONES ET AL., NATURE, vol. 321, 1986, pages 522 - 525
   E. KABAT ET AL.: "Sequences of Proteins of Immunological Interest", U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, 1983
   LANE. R.D., J. IMMUNOL. METH., vol. 81, 1985, pages 223 - 228
   ZIEGLER B., . HORM. METAB. RES., vol. 28, 1996, pages 11 - 15
   ALMAGROFRANSSON, FRONT BIOSCI., vol. 13, 2008, pages 1619 - 33
   ZIEGLER ET AL., HORM. METAB. RES., vol. 28, 1996, pages 11 - 15
   MARX, MONOCLONAL ANTIBODY PRODUCTION, ATLA, vol. 25, 1997, pages 121
   HUST ET AL., JOURNAL OF BIOTECHNOLOGY, vol. 152, 2011, pages 159 - 170
   SCHIITTE ET AL., PLOS ONE, vol. 4, 2009, pages e6625
   LORENZ ET AL., ANTIMICROB AGENTS CHEMOTHER., vol. 55, no. 1, 2011, pages 165 - 173
   COULTERHARRIS, J. IMMUNOL. METH., vol. 59., 1983
   LINDNER ET AL., CANCER RES., vol. 70, 2010, pages 277 - 87
   KAUFMANN ET AL., PNAS, vol. 107, 2010, pages 14727 - 32
   THOMAS ET AL., J. EXP. MED., vol. 206, 2009, pages 1913 - 27
   KONG ET AL., J. CELL BIOL., vol. 185, 2009, pages 1275 - 840
   MARIANI ET AL., MOL. IMMUNOL., vol. 28, 1991, pages 489 - 498
   BEALE, EXP COMP IMMUNOL, vol. 11, 1987, pages 287 - 96
   ELLERSON ET AL., FEBSLETTERS, vol. 24, no. 3, 1972, pages 318 - 22
   KERBELELLIOT, METH ENZYMOL, vol. 93, 1983, pages 113 - 147
   KULKARNI ET AL., CANCER IMMUNOL IMMUNOTHERAPY, vol. 19, 1985, pages 211 - 4
   LAMOVI, . METH ENZYMOL, vol. 121, 1986, pages 652 - 663
   PARHAM ET AL., J IMMUNOL METH, vol. 53, 1982, pages 133 - 73
   RAVCHAUDHURI ET AL., MOL IMMUNOL, vol. 22, no. 9, 1985, pages 1009 - 19
   ROUSSEAUX ET AL., MOL IMMUNOL, vol. 17, 1980, pages 469 - 82
   ROUSSEAUX ET AL., J IMMUNOL METH, vol. 64, 1983, pages 141 - 6
   WILSON ET AL., J IMMUNOL METH, vol. 138, 1991, pages 111 - 9
   HARRISBAIORATH, PROTEIN SCI., vol. 4, 1995, pages 306 - 310
   KIERS ET AL., SCIENTIFIC REPORTS, vol. 7, 2017, pages 40149
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.